Cipla launches Yurpeak (tirzepatide) for the treatment of obesity and type 2 diabetes in India

Tirzepatide is the first and only dual agonist glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors

Capricor's cell therapy shows breakthrough results in Duchenne muscular dystrophy trial

It's a development that marks a potential breakthrough for people living with the rare and debilitating disease Duchenne muscular dystrophy (DMD)

Dr Reddy's inks $370 million licensing deal to sell Immutep's cancer drug Eftilagimod Alfa

Dr Reddy’s will pay Immutep US$ 20 million upfront and could deliver as much as US$ 349.5 million in regulatory and commercial milestones

Roche’s Columvi combo doubles survival in hard-to-treat lymphoma

Columvi combined with gemcitabine and oxaliplatin dramatically extends survival in people with relapsed or refractory diffuse large B-cell lymphoma

AL-S Pharma shows promising Phase 2 results for its therapy in ALS treatment

Adverse events were similar to placebo, and no AP-101-induced antibody responses were detected

Pfizer’s therapy scores major win in Phase 3 trial for Hemophilia patients with inhibitors

HYMPAVZI’s safety profile was generally favorable

Freenome strikes SPAC deal to go public in 2026

Freenome expects the combined company to receive approximately $330 million in proceeds at closing

Groundbreaking study identifies 250 genes driving ME & long COVID

76 of 180 long COVID-associated genes also linked to ME

Praxis Precision hits milestone in fight against rare paediatric seizures

The EMBOLD study evaluated relutrigine for patients with SCN2A and SCN8A developmental and epileptic encephalopathies

Denali clinches $275 million royalty deal to power potential breakthrough Hunter Syndrome therapy